公开(公告)号：US10745387B2

公开(公告)日：2020-08-18

申请号：US15529798

申请日：2016-11-17

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. Keaney ,  John Wang ,  Baudouin Gerard ,  Kenzo Arai ,  Xiang Liu ,  Guo Zhu Zheng ,  Kazunobu Kira ,  Parcharee Tivitmahaisoon ,  Sudeep Prajapati ,  Nicholas C. Gearhart ,  Yoshihiko Kotake ,  Satoshi Nagao ,  Regina Mikie Kanada Sonobe ,  Masayuki Miyano ,  Norio Murai ,  Silvia Buonamici ,  Lihua Yu ,  Eunice Sun Park ,  Betty Chan ,  Peter G. Smith ,  Michael P. Thomas ,  Ermira Pazolli ,  Kian Huat Lim ,  Atsushi Endo ,  Arani Chanda

IPC: A61K31/496 ,  C07D295/182 ,  C07D405/14 ,  C07D405/06 ,  A61P35/02

Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.

公开(公告)号：US20180318312A1

公开(公告)日：2018-11-08

申请号：US15755225

申请日：2016-08-30

Applicant: Lihua YU ,  Kian Huat LIM ,  Jacob D. FEALA ,  Silvia BUONAMICI ,  Yoshiharu MIZUI ,  Peter G. SMITH ,  Ping ZHU ,  Eunice Sun PARK ,  Michael W. SEILER ,  Marco Peter FEKKES ,  Eisai R&D Management Co., Ltd.

Inventor： Lihua Yu ,  Kian Huat Lim ,  Jacob D. Feala ,  Silvia Buonamici ,  Yoshiharu Mizui ,  Peter G. Smith ,  Ping Zhu ,  Eunice Sun Park ,  Michael W. Seiler ,  Marco Peter Fekkes

IPC: A61K31/55 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/495 ,  C12Q1/6886 ,  C12Q1/02

CPC classification number: A61K31/55 ,  A61K31/4545 ,  A61K31/495 ,  A61P35/00 ,  C12Q1/025 ,  C12Q1/6806 ,  C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.